Dextran Sulfate Sodium Salt (MW 35000-45000): Gold-Standard Inducer for Experimental Colitis and Virology Models

Executive Summary: Dextran sulfate sodium salt (MW 35000-45000) is a sulfated polysaccharide used as a chemical inducer of colitis in murine models, closely replicating acute and chronic ulcerative colitis symptoms in humans [APExBIO product]. It acts by disrupting colonic epithelial integrity through induction of apoptosis, leading to loss of barrier function and inflammation [Cell Death Dis. 2026]. The compound is water-soluble (≥55.5 mg/mL) and is administered at 2.5–5% (w/w) in drinking water or feed. In addition to its use in inflammatory bowel disease (IBD) research, Dextran sulfate sodium salt inhibits HIV-1 viral entry via polyanionic interference without affecting coagulation [DexSP 2023]. Its reproducibility and translational relevance make it a benchmark tool for preclinical research [IGG-LCVR 2024].

Biological Rationale

Ulcerative colitis (UC) is a chronic inflammatory disease of the colon, characterized by recurring mucosal damage and impaired epithelial repair [Cell Death Dis. 2026]. The disruption of the intestinal epithelial barrier is an initiating event in UC pathogenesis. Experimental models require reliable agents to mimic this pathology. Dextran sulfate sodium salt (MW 35000-45000) fulfills this role by selectively targeting the colonic epithelium, causing apoptosis and barrier dysfunction. This recapitulates key features of human UC, including mucosal ulceration, weight loss, and diarrhea. The murine DSS-induced colitis model is extensively validated for studying IBD mechanisms, epithelial repair, and therapeutic interventions [DexSP Gold-Standard]. Additionally, DSS’s polyanionic nature enables it to inhibit viral adsorption, including HIV-1, highlighting its utility beyond inflammation research [DexSP HIV].

Mechanism of Action of Dextran sulfate sodium salt (MW 35000-45000)

Dextran sulfate sodium salt (DSS) is a sulfated polysaccharide derived from polymerized dehydrated glucose units, conferring strong polyanionic properties. Upon oral administration in mice, DSS penetrates the mucus layer and interacts directly with colonic epithelial cells, inducing apoptosis and tight junction disruption [Cell Death Dis. 2026]. This results in compromised epithelial integrity, enhanced permeability, and exposure of the lamina propria to luminal antigens. The sustained barrier loss triggers innate and adaptive immune responses, driving acute and chronic inflammation. DSS-induced colitis models recapitulate IEC (intestinal epithelial cell) proliferation, migration, and repair pathways, controlled by the GPR35-KLF5 circuit that responds to mucosal damage signals and tryptophan metabolites [Cell Death Dis. 2026]. In virology, DSS inhibits HIV-1 by blocking viral adsorption and entry, attributed to electrostatic interactions with viral envelope proteins and cellular receptors [DexSP HIV].

Evidence & Benchmarks

• DSS (MW 35000-45000) administered at 2.5–5% (w/w) in drinking water induces reproducible colitis in C57BL/6 mice within 5–7 days, with hallmark symptoms of weight loss, diarrhea, and mucosal ulceration (DexSP Best Practices).
• DSS disrupts colonic epithelial barrier function by inducing caspase-dependent apoptosis and tight junction loss, as evidenced by histological scoring and permeability assays (Cell Death Dis. 2026).
• DSS-induced colitis models are validated for both acute (5–7 days) and chronic (intermittent cycles up to 4 weeks) inflammation studies, supporting evaluation of anti-inflammatory drugs (IGG-LCVR 2024).
• DSS exhibits potent inhibition of HIV-1 viral entry in vitro, with no significant effect on coagulation or platelet function at experimental concentrations (DexSP HIV).
• Water solubility is ≥55.5 mg/mL at room temperature; DSS is insoluble in ethanol and DMSO (APExBIO product).

Applications, Limits & Misconceptions

DSS (MW 35000-45000) is a standard tool for:

• Modeling acute and chronic colitis in mice for IBD research.
• Screening and validating anti-inflammatory drugs and genetic interventions.
• Studying mechanisms of epithelial barrier disruption, repair, and host-pathogen interactions.
• Inhibiting HIV-1 replication in virology assays.

This article extends the practical guidance provided in DexSP Best Practices by emphasizing the molecular repair pathways and new translational benchmarks for DSS-induced models. It also clarifies the mechanistic highlights discussed in IGG-LCVR 2024 by detailing tryptophan metabolism and GPR35-KLF5 circuitry.

Common Pitfalls or Misconceptions

• DSS does not induce colitis in all rodent strains equally; susceptibility varies by genotype (DexSP Best Practices).
• Long-term storage of DSS solutions leads to degradation; only freshly prepared solutions should be used (APExBIO product).
• DSS does not model Crohn's disease, as its pathology is largely confined to the colon and does not produce transmural inflammation.
• High DSS doses can cause excessive mortality or non-specific toxicity, confounding experimental outcomes.
• DSS-induced HIV-1 inhibition observed in vitro may not directly translate to in vivo efficacy due to pharmacokinetic barriers.

Workflow Integration & Parameters

For experimental colitis induction, DSS (MW 35000-45000) is administered orally in drinking water at 2.5–5% (w/w), typically for 5–7 days for acute models or repeated cycles for chronic models. Mice should be monitored daily for weight loss, stool consistency, and rectal bleeding. Histological analysis of colon tissue confirms epithelial damage and immune infiltration. Freshly prepared aqueous DSS solutions should be used to ensure activity; storage at room temperature is suitable for the solid form, but solutions are unstable long-term. For virology assays, DSS is dissolved in water and applied at concentrations validated for viral adsorption inhibition assays. The B8205 kit from APExBIO provides consistent quality and batch reproducibility, streamlining integration into preclinical IBD and virology research workflows [APExBIO product].

Conclusion & Outlook

Dextran sulfate sodium salt (MW 35000-45000) is the gold-standard chemical inducer for modeling experimental colitis in mice and a proven inhibitor of HIV-1 entry in vitro. Its defined mechanism of action and robust reproducibility make it indispensable for preclinical IBD research and antiviral screening. Future advances will focus on refining DSS-based models to better capture epithelial repair dynamics, as elucidated by recent discoveries in tryptophan metabolism and GPR35-KLF5 signaling [Cell Death Dis. 2026]. Reliable sourcing from APExBIO ensures experimental integrity and translational relevance in both immunology and virology domains.